<?xml version='1.0' encoding='utf-8'?>
<document id="24065861"><sentence text="Assessment of the roles of P-glycoprotein and cytochrome P450 in triptolide-induced liver toxicity in sandwich-cultured rat hepatocyte model."><entity charOffset="65-75" id="DDI-PubMed.24065861.s1.e0" text="triptolide" /></sentence><sentence text="Triptolide (TP), a main bioactive component of Tripterygium wilfordii Hook F"><entity charOffset="0-10" id="DDI-PubMed.24065861.s2.e0" text="Triptolide" /><entity charOffset="12-14" id="DDI-PubMed.24065861.s2.e1" text="TP" /><pair ddi="false" e1="DDI-PubMed.24065861.s2.e0" e2="DDI-PubMed.24065861.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24065861.s2.e0" e2="DDI-PubMed.24065861.s2.e1" /></sentence><sentence text=", is a promising agent for treatment of autoimmune diseases" /><sentence text=" However, a high incidence of dose-limiting hepatotoxicity was observed in the clinic" /><sentence text=" Sandwich-cultured rat hepatocyte model was used in this study to identify the involvement of P-glycoprotein (P-gp) in TP disposition and to evaluate TP-induced hepatotoxicity after modulation of P-gp by the known inhibitors, ritonavir and tariquidar, and known inducers, phenobarbital, quercetin, and H(2)O(2)"><entity charOffset="226-235" id="DDI-PubMed.24065861.s5.e0" text="ritonavir" /><entity charOffset="272-285" id="DDI-PubMed.24065861.s5.e1" text="phenobarbital" /><entity charOffset="287-296" id="DDI-PubMed.24065861.s5.e2" text="quercetin" /><entity charOffset="302-310" id="DDI-PubMed.24065861.s5.e3" text="H(2)O(2)" /><entity charOffset="119-126" id="DDI-PubMed.24065861.s5.e4" text="TP" /><entity charOffset="150-157" id="DDI-PubMed.24065861.s5.e5" text="TP" /><pair ddi="false" e1="DDI-PubMed.24065861.s5.e4" e2="DDI-PubMed.24065861.s5.e4" /><pair ddi="false" e1="DDI-PubMed.24065861.s5.e4" e2="DDI-PubMed.24065861.s5.e5" /><pair ddi="false" e1="DDI-PubMed.24065861.s5.e4" e2="DDI-PubMed.24065861.s5.e0" /><pair ddi="false" e1="DDI-PubMed.24065861.s5.e4" e2="DDI-PubMed.24065861.s5.e1" /><pair ddi="false" e1="DDI-PubMed.24065861.s5.e4" e2="DDI-PubMed.24065861.s5.e2" /><pair ddi="false" e1="DDI-PubMed.24065861.s5.e4" e2="DDI-PubMed.24065861.s5.e3" /><pair ddi="false" e1="DDI-PubMed.24065861.s5.e5" e2="DDI-PubMed.24065861.s5.e5" /><pair ddi="false" e1="DDI-PubMed.24065861.s5.e5" e2="DDI-PubMed.24065861.s5.e0" /><pair ddi="false" e1="DDI-PubMed.24065861.s5.e5" e2="DDI-PubMed.24065861.s5.e1" /><pair ddi="false" e1="DDI-PubMed.24065861.s5.e5" e2="DDI-PubMed.24065861.s5.e2" /><pair ddi="false" e1="DDI-PubMed.24065861.s5.e5" e2="DDI-PubMed.24065861.s5.e3" /><pair ddi="false" e1="DDI-PubMed.24065861.s5.e0" e2="DDI-PubMed.24065861.s5.e0" /><pair ddi="false" e1="DDI-PubMed.24065861.s5.e0" e2="DDI-PubMed.24065861.s5.e1" /><pair ddi="false" e1="DDI-PubMed.24065861.s5.e0" e2="DDI-PubMed.24065861.s5.e2" /><pair ddi="false" e1="DDI-PubMed.24065861.s5.e0" e2="DDI-PubMed.24065861.s5.e3" /><pair ddi="false" e1="DDI-PubMed.24065861.s5.e1" e2="DDI-PubMed.24065861.s5.e1" /><pair ddi="false" e1="DDI-PubMed.24065861.s5.e1" e2="DDI-PubMed.24065861.s5.e2" /><pair ddi="false" e1="DDI-PubMed.24065861.s5.e1" e2="DDI-PubMed.24065861.s5.e3" /><pair ddi="false" e1="DDI-PubMed.24065861.s5.e2" e2="DDI-PubMed.24065861.s5.e2" /><pair ddi="false" e1="DDI-PubMed.24065861.s5.e2" e2="DDI-PubMed.24065861.s5.e3" /></sentence><sentence text=" Our data showed that biliary clearance of TP reduced 73"><entity charOffset="43-44" id="DDI-PubMed.24065861.s6.e0" text="TP" /></sentence><sentence text="7% and 84" /><sentence text="2% upon treatment of ritonavir (25 µM) and tariquidar (5 µM), respectively"><entity charOffset="21-30" id="DDI-PubMed.24065861.s8.e0" text="ritonavir" /></sentence><sentence text=" In contrast, increases of 346%, 280%, and 273% in biliary clearance of TP were observed with treatment of phenobarbital (1"><entity charOffset="107-120" id="DDI-PubMed.24065861.s9.e0" text="phenobarbital" /><entity charOffset="72-84" id="DDI-PubMed.24065861.s9.e1" text="TP" /><pair ddi="false" e1="DDI-PubMed.24065861.s9.e1" e2="DDI-PubMed.24065861.s9.e1" /><pair ddi="false" e1="DDI-PubMed.24065861.s9.e1" e2="DDI-PubMed.24065861.s9.e0" /></sentence><sentence text="0 mM), quercetin (20 µM), and H(2)O(2) (0"><entity charOffset="7-16" id="DDI-PubMed.24065861.s10.e0" text="quercetin" /><entity charOffset="30-38" id="DDI-PubMed.24065861.s10.e1" text="H(2)O(2)" /><pair ddi="false" e1="DDI-PubMed.24065861.s10.e0" e2="DDI-PubMed.24065861.s10.e0" /><pair ddi="false" e1="DDI-PubMed.24065861.s10.e0" e2="DDI-PubMed.24065861.s10.e1" /></sentence><sentence text="5 mM), respectively" /><sentence text=" The TP-induced hepatotoxicity increased by twofold when CYP activity was blocked by 1-aminobenzotriazole, suggesting that CYP and P-gp may both contribute to the detoxification of TP in the SCRH model"><entity charOffset="85-105" id="DDI-PubMed.24065861.s12.e0" text="1-aminobenzotriazole" /><entity charOffset="5-24" id="DDI-PubMed.24065861.s12.e1" text="TP" /><entity charOffset="181-200" id="DDI-PubMed.24065861.s12.e2" text="TP" /><pair ddi="false" e1="DDI-PubMed.24065861.s12.e1" e2="DDI-PubMed.24065861.s12.e1" /><pair ddi="false" e1="DDI-PubMed.24065861.s12.e1" e2="DDI-PubMed.24065861.s12.e0" /><pair ddi="false" e1="DDI-PubMed.24065861.s12.e1" e2="DDI-PubMed.24065861.s12.e2" /><pair ddi="false" e1="DDI-PubMed.24065861.s12.e0" e2="DDI-PubMed.24065861.s12.e0" /><pair ddi="false" e1="DDI-PubMed.24065861.s12.e0" e2="DDI-PubMed.24065861.s12.e2" /></sentence><sentence text=" In addition, hepatotoxicity and the expression of apoptosis proteins Bax and Bcl-2 were correlated qualitatively with the TP exposure duration and its intracellular concentration, which, in turn, can be modulated by P-gp inhibitors or inducers"><entity charOffset="123-124" id="DDI-PubMed.24065861.s13.e0" text="TP" /></sentence><sentence text=" Our results for the first time demonstrated that in addition to CYP-mediated metabolism, P-gp also plays an important role in the disposition of TP and TP-induced hepatotoxicity"><entity charOffset="146-147" id="DDI-PubMed.24065861.s14.e0" text="TP" /><entity charOffset="153-154" id="DDI-PubMed.24065861.s14.e1" text="TP" /><pair ddi="false" e1="DDI-PubMed.24065861.s14.e0" e2="DDI-PubMed.24065861.s14.e0" /><pair ddi="false" e1="DDI-PubMed.24065861.s14.e0" e2="DDI-PubMed.24065861.s14.e1" /></sentence><sentence text=" Thus, the modulation of canalicular P-gp has a potential to cause drug-drug interaction between TP and the coadministered P-gp inhibitors or inducers in the clinic"><entity charOffset="97-98" id="DDI-PubMed.24065861.s15.e0" text="TP" /></sentence><sentence text="" /></document>